Subconjunctival injection of XG-102, a c-Jun N-terminal kinase inhibitor peptide, in the treatment of endotoxin-induced uveitis in rats

Journal of Ocular Pharmacology and Therapeutics

Volumn 31, Issue 1, 2015, Pages 17-24

  El Zaoui, Ikram ^a   Touchard, Elodie ^a   Berdugo, Marianne ^a   Abadie, Claire ^b   Kowalczuk, Laura ^a   Deloche, Catherine ^b   Zhao, Min ^a   Naud, Marie Christine ^a   Combette, Jean Marc ^b   Behar Cohen, Francine ^a,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b Solid Drug Development SA   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; DEXAMETHASONE SODIUM PHOSPHATE; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG; XG 102; ANTI-INFLAMMATORY AGENTS; CHEMOKINE CXCL1; CXCL1 PROTEIN, RAT; D-JNKI-1; LIPOPOLYSACCHARIDES; NITRIC OXIDE SYNTHASE TYPE II; NOS2 PROTEIN, RAT; PEPTIDES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-JUN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENDOTOXIN-INDUCED UVEITIS; FEMALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SCORING SYSTEM; WESTERN BLOTTING; ANIMALS; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMICALLY INDUCED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG EFFECTS; INJECTIONS, INTRAOCULAR; INJECTIONS, INTRAVENOUS; METABOLISM; PHOSPHORYLATION; RANDOM ALLOCATION; RATS; RATS, INBRED LEW; UVEITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHEMOKINE CXCL1; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; INJECTIONS, INTRAOCULAR; INJECTIONS, INTRAVENOUS; LIPOPOLYSACCHARIDES; NITRIC OXIDE SYNTHASE TYPE II; PEPTIDES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-JUN; RANDOM ALLOCATION; RATS; RATS, INBRED LEW; UVEITIS;

EID: 84920829953     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2014.0019     Document Type: Article

References (24)

1. De Smet, M.D., Taylor, S.R., Bodaghi, B., Miserocchi, E., Murray, P.I., Pleyer, U., Zierhut, M., Barisani-Asenbauer, T., LeHoang, P., and Lightman, S. Understanding uveitis. The impact of research on visual outcomes. Prog. Retin Eye Res. 30:452-470, 2011.
2. Mercieca, K., and Jones, N.P. Treatment of acute anterior uveitis in the community, as seen in an emergency eye centre. A lesson for the general practitioner? Eur. J. Gen. Pract. 18:26-29, 2012.
3. Medeiros, R., Rodrigues, G.B., Figueiredo, C.P., Rodrigues, E.B., Grumman Jr., A., Menezes-de-Lima Jr., O., Passos, G.F., and Calixto, J.B. Molecular mechanisms of topical anti-inflammatory effects of lipoxinA(4) in endotoxin-induced uveitis. Mol. Pharmacol. 74:154-161, 2008.
4. Taylor, S.R., Isa, H., Joshi, L., and Lightman, S. New developments in corticosteroid therapy for uveitis. Ophthalmologica 224:46-53, 2010.
5. Agrawal, R.V., Murthy, S., Sangwan, V., and Biswas, J. Current approach in diagnosis and management of anterior uveitis. Indian J. Ophthalmol. 58:11-19, 2010.
6. Abad, S., Sève, P., Dhote, R., and Brézin, A.P. Uveítes et médecine interne. Stratégies diagnostique et thérapeutique. La Revue de Médecine Interne 30:492-500, 2009.
7. De Smet, M.D. Corticosteroid intravitreal implants. Dev. Ophthalmol. 51:122-133, 2012.
8. Tsai, M.L., Horng, C.T., Chen, S.L., Xiao, X., Wang, C.H., and Tsao, Y.P. Suppression of experimental uveitis by a recombinant adenoassociated virus vector encoding interleukin-1 receptor antagonist. Mol. Vis. 15:1542-1552, 2009.
9. Han, Z., Boyle, D.L., Aupperle, K.R., Bennett, B., Manning, A.M., and Firestein, G.S. JunN-terminal kinase in rheumatoid arthritis. J. Pharmacol. Exp. Ther. 291:124-130, 1999.
10. Clancy, R., Rediske, J., Koehne, C., Stoyanovsky, D., Amin, A., Attur, M., Iyama, K., and Abramson, S.B. Activation of stress-activated protein kinase in osteoarthritic cartilage. Evidence for nitric oxide dependence. Osteoarthritis Cartilage 9:294-299, 2001.
11. Hirt, L., Badaut, J., Thevenet, J., Granziera, C., Regli, L., Maurer, F., Bonny, C., and Bogousslavsky, J. D-JNKI1, a cell-penetrating c-Jun-N-terminal kinase inhibitor, protects against cell death in severe cerebral ischemia. Stroke. 35:1738-1743, 2004.
12. Touchard, E., Omri, S., Naud, M.C., Berdugo, M., Deloche, C., Abadie, C., Jonet, L., Jeanny, J.C., Crisanti, P., De Kozak, Y., Combette, J.M., and Behar-Cohen, F. A peptide inhibitor of c-jun N-terminal kinase for the treatment of endotoxin-induced uveitis. Invest. Ophthalmol. Vis. Sci. 51: 4683-4693, 2010.
13. Rosenbaum, J.T., McDevitt, H.O., Guss, R.B., and Egbert, R. Endotoxin-induced uveitis in rats as a model for human disease. Nature. 268:611-613, 1980.
14. Hashida, M., Fukushima, A., Zhang, J., Kodama, H., and Ueno, H. Involvement of superoxide generated by polymorphonuclear leukocytes in endotoxin-induced uveitis. Graefes Arch. Clin. Exp. Ophthalmol. 238:359-365, 2000.
15. Behar-Cohen, F.F., Parel, J.M., Pouliquen, Y., Thillaye-Goldenberg, B., Goureau, O., Heydolph, S., Courtois, Y., and De Kozak, Y. Iontophoresis of dexamethasone in the treatment of endotoxin-induced-uveitis in rats. Exp. Eye Res. 65:533-545, 1997.
16. Ip, Y.T., and Davis, R.J. Signal transduction by the c-Jun N-terminal kinase ( JNK)-from inflammation to development. Curr. Opin. Cell Biol. 10:205-219, 1998.
17. Willaime-Morawek, S., Brami-Cherrier, K., Mariani, J., Caboche, J., and Brugg, B. C-Jun N-terminal kinases/c-Jun and p38 pathway scooperate in ceramide-induced neuronal apoptosis. Neuroscience. 119:387-397, 2003.
18. Chi, Z.L., Hayasaka, S., Zhang, X.Y., Cui, H.S., and Hayasaka, Y. A cholinergic agonist attenuates endotoxininduced uveitis in rats. Invest. Ophthalmol. Vis. Sci. 48: 2719-2725, 2007.
19. Reinecke, K., Eminel, S., Dierck, F., Roessner, W., Kersting, S., Chromik, A.M., Gavrilova, O., Laukevicience, A., Leuschner, I., Waetzig, V., Rosenstiel, P., Herdegen, T., and Sina, C. The JNK inhibitor XG-102 protects against TNBS-induced colitis. PLoS One 7:e30985, 2012.
20. Bonny, C., Oberson, A., Negri, S., Sauser, C., and Schorderet, D.F. Cell-permeable peptide inhibitors of JNK novel blockers of b-cell death. Diabetes. 50:77-82, 2001.
21. El Sanharawi, M., Kowalczuk, L., Touchard, E., Omri, S., de Kozak, Y., and Behar-Cohen, F. Protein delivery for retinal diseases. From basic considerations to clinical applications. Prog. Retin. Eye Res. 29:443-465, 2010.
22. Weijtens, O., Feron, E.J., Schoemaker, R.C., Cohen, A.F., Lentjes, E.G., Romijn, F.P., and Van Meurs, J.C. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am. J. Ophthalmol. 128: 192-197, 1999.
23. Weijtens, O., Schoemaker, R.C., Cohen, A.F., Romijn, F.P., Lentjes, E.G., Van Rooij, J., and Van Meurs, J.C. Dexamethasone concentration in vitreous and serum after oral administration. Am. J. Ophthalmol. 125:673-679, 1998.
24. Weijtens, O., Van Der Sluijs, F.A., Schoemaker, R.C., Lentjes, E.G., Cohen, A.F., Romijn, F.P., and Van Meurs, J.C. Peribulbar corticosteroid injection. Vitreal and serum concentrations after dexamethasone disodium phosphate injection. Am. J. Ophthalmol. 123:358-363, 1997.